Life Science Investing uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Life Science Investing uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
Life Science Investing uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease
Life Science Investing uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in ?-Gal A Enzyme Activity in Patients with Fabry Disease
